市場調查報告書
商品編碼
1378996
寡核苷酸合成市場:2023-2028 年全球產業趨勢、佔有率、規模、成長、機會與預測Oligonucleotide Synthesis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
2022年全球寡核苷酸合成市場規模達27億美元。展望未來, IMARC Group預計到2028年市場規模將達到55億美元,2022-2028年複合年成長率(CAGR)為12.6%。遺傳疾病在大眾中的日益流行、新型治療策略的開發以及使用小干擾 RNA (siRNA) 和反義寡核苷酸的療法的廣泛採用是推動市場的一些主要因素。
寡核苷酸合成是指依照預定序列建構短 DNA 或 RNA 分子(稱為寡核苷酸)的過程。它們的長度範圍可以從幾個鹼基到大約 200 個核苷酸。該過程是在受控實驗室環境中以化學方式完成的,通常使用固相亞磷醯胺化學。在這種方法中,核苷酸被順序添加到不斷成長的鏈中,每次添加都涉及一系列化學反應。該技術使科學家能夠產生用於各種應用的客製化寡核苷酸,包括基因合成、聚合酶鍊式反應 (PCR)、基因編輯工具(如 CRISPR-Cas9)和分子診斷測試。寡核苷酸合成的進步極大地加速了基因組學和分子生物學的研究,為醫學和生物學研究的許多突破奠定了基礎。
大眾遺傳疾病盛行率的上升主要推動了全球市場。這就需要開發新的治療策略,其中基於寡核苷酸的療法發揮重要作用。例如,正在研究使用小干擾 RNA (siRNA) 和反義寡核苷酸的療法,並將其用於治療遺傳性疾病,例如杜氏肌肉營養不良症和脊髓性肌肉萎縮症。因此,遺傳疾病的日益普及推動了全球範圍內的需求。同時,生物資訊學和資料科學的發展對寡核苷酸合成產業產生直接影響。分析大型基因組資料集的能力不斷增強也對市場產生了積極影響。因此,計算能力的提高正在推動對新型寡核苷酸合成的需求增加。此外,寡核苷酸,特別是反義寡核苷酸,已被證明是表觀遺傳學研究和治療的有效工具,有助於調節基因表達,從而創造了積極的市場前景。
醫療保健和製藥業的需求不斷成長
全球對個人化醫療和治療的需求正在迅速成長,導致寡核苷酸合成市場空前擴張。這些合成的序列是開發針對各種遺傳性疾病和疾病(包括癌症)的標靶療法的不可或缺的組成部分。同時,反義寡核苷酸、適體、siRNA 和免疫刺激寡核苷酸等治療性寡核苷酸的進步,透過特異性抑製或改變基因表達,正在徹底改變疾病治療。此外,客製化寡核苷酸的合成是疫苗生產的基礎,包括基於 mRNA 的 COVID-19 疫苗,該疫苗已被證明有效且現已廣泛使用。隨著製藥公司和研究人員不斷發現寡核苷酸在治療和預防疾病方面的新應用,寡核苷酸合成的需求即將上升。
技術進步與創新
寡核苷酸合成技術的穩定發展和完善正在推動市場成長。此外,合成製程的創新,包括高通量和自動化合成系統,提高了寡核苷酸生產的效率、準確性和可擴展性。此外,生物資訊學和合成生物學的發展,包括DNA定序和基因編輯(例如CRISPR-Cas9),在很大程度上依賴準確合成寡核苷酸的能力。這些進步允許創建具有更大複雜性和多樣性的客製化序列,並促進合成生物學中的快速原型測試,從而促進更有效的研究和開發。這些不斷的技術進步和發展也在為市場做出貢獻。
不斷加強的合作和夥伴關係
製藥公司、生技公司和研究機構之間的合作和夥伴關係已成為推動遺傳疾病寡核苷酸療法的開發和商業化的重要驅動力。這些合作匯集了不同的專業知識、資源和資金,創造了一個協同環境,加速將科學發現轉化為實際有效的治療方法。製藥公司在藥物開發、臨床試驗和監管流程方面擁有豐富的經驗,為此合作貢獻了重要的專業知識。他們擁有必要的基礎設施、知識和資源來應對藥物開發的複雜局面,並確保寡核苷酸療法符合安全性和有效性的監管標準。他們的參與有助於利用現有網路、製造能力和分銷管道簡化商業化之路。
IMARC Group提供了全球寡核苷酸合成市場報告各細分市場主要趨勢的分析,以及 2023-2028 年全球、區域和國家層面的預測。我們的報告根據產品、應用和最終用途對市場進行了分類。
合成寡核苷酸產品
試劑
裝置
服務
合成寡核苷酸產品主導市場
該報告根據產品提供了詳細的市場細分和分析。這包括合成的寡核苷酸產品、試劑、設備和服務。根據該報告,合成寡核苷酸產品代表了最大的部分。
製藥和生物技術公司對藥物發現和開發,特別是個人化醫療和標靶治療的需求不斷成長,推動了寡核苷酸合成產業中合成寡核苷酸產品的市場。同時,在次世代定序 (NGS) 和 CRISPR 基因編輯等技術的重大進步的推動下,基因組學和分子研究的興起,提高了合成寡核苷酸的需求。此外,寡核苷酸診斷應用的成長,例如遺傳性疾病和傳染病的 PCR 和微陣列檢測,正在推動市場向前發展。表觀遺傳學領域的不斷擴大也是一個關鍵促進因素,寡核苷酸在基因表現研究中發揮著至關重要的作用。此外,遺傳性疾病的日益普及以及由此產生的對涉及寡核苷酸的新型治療策略的需求進一步加速了合成寡核苷酸產品的市場成長。
PCR引子
PCR 檢測與試劑盒
定序
DNA微陣列
螢光原位雜合技術 (FISH)
反義寡核苷酸
其他
PCR引子佔據市場主導地位
報告還提供了基於應用程式的詳細市場細分和分析。這包括 PCR 引子、PCR 檢測和組合、定序、DNA 微陣列、螢光原位雜合技術 (FISH)、反義寡核苷酸等。根據報告,PCR 引子代表了最大的片段。
持續的全球健康危機推動了寡核苷酸合成產業對 PCR 引子的需求,需要進行廣泛的病毒檢測,其中 PCR 是主要方法。此外,PCR 在醫學診斷、法醫學以及檢測基因突變和傳染病的研究中的應用日益增多,也推動了對引子的需求。在基因組學和分子生物學領域,PCR 被認為是 DNA 定序、克隆和基因操作的重要工具,這種廣泛的用途進一步推動了對 PCR 引子合成的需求。除此之外,即時PCR和數位PCR等PCR技術的進步也在刺激需求方面發揮作用。此外,醫療保健和生命科學研究領域的資金不斷增加,導致 PCR 的使用擴大,從而推動了整個產業對 PCR 引子的需求。
製藥和生物技術公司
醫院和診斷實驗室
學術研究機構
學術研究機構主導市場
該報告根據產品提供了詳細的市場細分和分析。這包括製藥和生物技術公司、醫院和診斷實驗室以及學術研究機構。報告稱,學術研究機構佔比最大。
學術研究機構對寡核苷酸合成的需求是由基因組學和分子生物學研究的興起所推動的,特別是與基因表現、遺傳性疾病和新型治療策略的開發相關的研究。此外,依賴合成寡核苷酸的下一代定序 (NGS) 和 CRISPR 基因編輯等技術的進步正在刺激需求。此外,涉及生物資訊學和資料科學的跨學科研究的不斷成長趨勢,需要使用寡核苷酸進行資料驗證,進一步推動了這一需求。政府和機構對基因組學和生物技術研究的資助是另一個主要驅動力,使學術機構能夠投資於各種計畫的寡核苷酸合成。學術研究機構專注於基礎研究和發現,往往擁有前沿知識和創新理念。透過與業界合作,他們可以將科學發現轉化為實際應用和商業產品。
北美洲
美國
加拿大
亞太
中國
日本
印度
韓國
澳洲
印尼
其他
歐洲
德國
法國
英國
義大利
西班牙
俄羅斯
其他
拉丁美洲
巴西
墨西哥
其他
中東和非洲
北美表現出明顯的主導地位,佔據最大的寡核苷酸合成市場佔有率
該報告還對所有主要區域市場進行了全面分析,其中包括北美(美國和加拿大);亞太地區(中國、日本、印度、韓國、澳洲、印尼等);歐洲(德國、法國、英國、義大利、西班牙、俄羅斯等);拉丁美洲(巴西、墨西哥等);以及中東和非洲。
北美寡核苷酸合成市場由強勁的製藥和生物技術產業推動,專注於藥物發現和開發。該地區對個人化醫療和標靶治療的重視進一步推動了這一需求。此外,北美複雜的醫療保健系統和先進的診斷能力增加了診斷分析中對寡核苷酸的需求。該地區還擁有許多頂級學術和研究機構,進行廣泛的基因組學和分子生物學研究,這需要寡核苷酸合成。此外,政府和私營部門對醫療保健和生命科學研究,特別是基因組學和個人化醫療的大力投資,推動了北美工業的成長。此外,北美基於寡核苷酸的療法的輸送系統和配方的進步表明該地區致力於突破該領域的創新界限。這些發展不僅有助於市場的成長,而且有可能徹底改變各種疾病的治療,包括遺傳性疾病、癌症和罕見疾病。
由於開發新生產設施、升級現有設施以及實施更有效率的生產流程的投資不斷增加,全球寡核苷酸合成市場正在經歷顯著成長。因此,該公司正在大力投資研發以創新其產品,包括開發新的合成技術、提高合成的規模和準確性,以及創造新型寡核苷酸產品以支持診斷、治療和研究中的各種應用。同時,公司正進入策略合作、夥伴關係和收購,共同開發基於寡核苷酸的藥物、共享技術和專業知識或拓展新市場。此外,反義寡核苷酸、siRNA 和 miRNA 等療法的引入為治療包括遺傳性疾病和癌症在內的多種疾病提供了新途徑,對市場產生了積極影響。此外,主要參與者正在提供寡核苷酸的客製化合成服務。這使得研究人員和開發人員能夠根據自己的需求訂購特定的寡核苷酸序列,這在基因組學、分子生物學和個人化醫療等領域尤其重要。
安捷倫科技公司
比奧萊吉奧有限公司
生物合成公司
歐陸基因公司
金斯瑞
地平線探索有限公司
Integrated DNA Technologies Inc(丹納赫公司)
鐘化 Eurogentec SA(鐘化株式會社)
LGC有限公司
Nitto Denko Avecia Inc(日東電工株式會社)
賽默飛世爾科技公司
2023年5月,金斯瑞擴大了其位於中國江蘇鎮江的主要製造工廠的規模,用於生產寡核苷酸和勝肽。此次擴張建立在金斯瑞 20 年來為世界各地的科學家提供一流寡核苷酸和勝肽的歷史基礎上。
2023 年 1 月,安捷倫科技公司宣布增加治療性核酸(也稱為寡核苷酸)的產量。該舉措是該行業為應對快速發展而進行的一系列投資中的最新舉措。安捷倫位於科羅拉多州弗雷德里克的工廠宣佈於 2020 年安裝一條生產線,預計今年稍後開始營運,該項目將增加兩條寡核苷酸生產線。
2022 年 2 月,Kaneka Eurogentec SA(鐘化株式會社)表示,為美國客戶批量生產的 25 g mRNA 已在其 mRNA 合成工廠成功生產。在其位於比利時的現有工廠中,Eurogentec 的 GMP mRNA 生產服務提供 GMP 材料的體外轉錄 (IVT)、純化、品質控制和批量放行,最大可達 25 g 規模。
The global oligonucleotide synthesis market size reached US$ 2.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.5 Billion by 2028, exhibiting a growth rate (CAGR) of 12.6% during 2022-2028. The growing prevalence of genetic diseases among the masses, the development of novel therapeutic strategies, and the widespread adoption of therapies using small interfering RNAs (siRNAs), and antisense oligonucleotides are some of the major factors propelling the market.
Oligonucleotide synthesis refers to the process of constructing short DNA or RNA molecules, called oligonucleotides, in a predetermined sequence. These can range from just a few bases to around 200 nucleotides in length. The process is accomplished chemically in a controlled laboratory environment, typically using solid phase phosphoramidite chemistry. In this method, nucleotides are sequentially added to a growing chain, each addition involving a series of chemical reactions. This technology enables scientists to generate custom-made oligonucleotides for various applications including gene synthesis, polymerase chain reaction (PCR), gene editing tools, such as CRISPR-Cas9, and molecular diagnostic tests. Advances in oligonucleotide synthesis have dramatically accelerated research in genomics and molecular biology, underpinning many breakthroughs in medical and biological research.
The rising prevalence of genetic diseases among the masses majorly drives the global market. This necessitates the development of novel therapeutic strategies, where oligonucleotide-based therapies play a significant role. For instance, therapies using small interfering RNAs (siRNAs) and antisense oligonucleotides are being investigated and utilized in the treatment of genetic disorders, such as Duchenne muscular dystrophy and spinal muscular atrophy. As such, the growing prevalence of genetic diseases drives the demand on the global level. Along with this, the growth of bioinformatics and data science has a direct impact on the oligonucleotide synthesis industry. The escalating capacity to analyze large genomic datasets is also positively influencing the market. Therefore, the rising computational capability is driving an increased demand for the synthesis of novel oligonucleotides. Furthermore, oligonucleotides particularly antisense oligonucleotides, have been shown to be effective tools in epigenetic research and therapy, helping to modulate gene expression, which is creating a positive market outlook.
Rising Demand in the Healthcare and Pharmaceutical Industries
The global demand for personalized medicine and therapeutics is rapidly increasing, leading to an unprecedented expansion in the oligonucleotide synthesis market. These synthesized sequences are integral components in developing targeted therapies for various genetic disorders and diseases, including cancer. Along with this, the advancement of therapeutic oligonucleotides, such as antisense oligonucleotides, aptamers, siRNAs, and immunostimulatory oligonucleotides, is revolutionizing disease treatment by specifically inhibiting or altering gene expression. Furthermore, the synthesis of custom oligonucleotides is fundamental to the production of vaccines, including mRNA-based COVID-19 vaccines, which have proven effective and are now widely used. As pharmaceutical companies and researchers continue to discover novel applications for oligonucleotides in the treatment and prevention of diseases, the demand for oligonucleotide synthesis is poised to rise.
Technological Advancements and Innovation
The steady development and refinement of oligonucleotide synthesis technologies are driving market growth. In addition, innovations in the synthesis process, including high-throughput and automated synthesis systems, have increased the efficiency, accuracy, and scalability of oligonucleotide production. Moreover, developments in bioinformatics and synthetic biology, including DNA sequencing and gene editing (e.g., CRISPR-Cas9), heavily rely on the ability to synthesize oligonucleotides accurately. These advancements allow for the creation of custom sequences with greater complexity and diversity and facilitate rapid prototype testing in synthetic biology, thereby fostering more efficient research and development. These continuous technological advancements and developments are also contributing to the market.
Growing Collaborations and Partnerships
Collaborations and partnerships between pharmaceutical companies, biotechnology firms, and research institutions have become essential drivers in advancing the development and commercialization of oligonucleotide therapies for genetic diseases. These collaborations bring together diverse expertise, resources, and funding, creating a synergistic environment that accelerates the translation of scientific discoveries into practical and effective treatments. Pharmaceutical companies, with their experience in drug development, clinical trials, and regulatory processes, contribute vital expertise to the collaboration. They have the infrastructure, knowledge, and resources necessary to navigate the complex landscape of drug development and ensure that oligonucleotide therapies meet regulatory standards for safety and efficacy. Their involvement helps streamline the path to commercialization by leveraging existing networks, manufacturing capabilities, and distribution channels.
IMARC Group provides an analysis of the key trends in each segment of the global oligonucleotide synthesis market report, along with forecasts at the global, regional and country levels from 2023-2028. Our report has categorized the market based on product, application and end use.
Synthesized Oligonucleotide Products
Reagents
Equipment
Services
Synthesized oligonucleotide products dominate the market
The report has provided a detailed breakup and analysis of the market based on the product. This includes synthesized oligonucleotide products, reagents, equipment, and services. According to the report, synthesized oligonucleotide products represented the largest segment.
The market for synthesized oligonucleotide products in the oligonucleotide synthesis industry is being driven by the ever-increasing demand from pharmaceutical and biotechnological companies for drug discovery and development, especially for personalized medicine and targeted therapeutics. Along with this, the rise in genomics and molecular research, fueled by significant advancements in technologies such as Next Generation Sequencing (NGS) and CRISPR gene-editing, is enhancing the requirement for synthesized oligonucleotides. Additionally, the growth in diagnostic applications of oligonucleotides, such as in PCR and microarray assays for genetic and infectious diseases, is propelling the market forward. The expanding field of epigenetics also represents a key driver, with oligonucleotides playing a crucial role in gene expression studies. Moreover, the increasing prevalence of genetic disorders and the resultant demand for novel therapeutic strategies involving oligonucleotides further accelerates the market growth for synthesized oligonucleotide products.
PCR Primers
PCR Assays and Panels
Sequencing
DNA Microarrays
Fluorescence In-Situ Hybridization (FISH)
Antisense Oligonucleotides
Others
PCR primers dominate the market
A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes PCR primers, PCR assays and panels, sequencing, DNA microarrays, Fluorescence In-Situ Hybridization (FISH), antisense oligonucleotides, and others. According to the report, the PCR primers represented the largest segment.
The demand for PCR primers in the oligonucleotide synthesis industry is driven by the ongoing global health crisis necessitating extensive viral testing, in which PCR is a primary method. Furthermore, the increasing application of PCR in medical diagnostics, forensics, and research to detect genetic mutations and infectious diseases fuels the demand for primers. In the field of genomics and molecular biology, PCR is considered a crucial tool for DNA sequencing, cloning, and genetic manipulation, and this broad utilization further drives the need for PCR primer synthesis. Apart from this, technological advancements in PCR techniques, such as real-time PCR and digital PCR, are also playing a role in boosting demand. Moreoevr, the growing funding for research in healthcare and life sciences has resulted in expanded use of PCR, thus driving the demand for PCR primers in the overall industry.
Pharmaceutical and Biotechnology Companies
Hospital and Diagnostic Laboratories
Academic Research Institutes
Academic research institutes dominate the market
The report has provided a detailed breakup and analysis of the market based on the product. This includes pharmaceutical and biotechnology companies, hospital and diagnostic laboratories, and academic research institutes. According to the report, academic research institutes represented the largest segment.
The demand for oligonucleotide synthesis in academic research institutes is driven by a rise in genomics and molecular biology research, particularly studies related to gene expression, genetic disorders, and the development of novel therapeutic strategies. Additionally, advancements in technologies such as Next-Generation Sequencing (NGS) and CRISPR gene-editing, which rely on synthesized oligonucleotides, are stimulating demand. In addition, the rising trend of interdisciplinary studies involving bioinformatics and data science, which necessitate the use of oligonucleotides for data validation, further drives the need. Governmental and institutional funding for genomics and biotechnology research is another major driver, enabling academic institutes to invest in oligonucleotide synthesis for various projects. Academic research institutes, with their focus on fundamental research and discovery, often possess cutting-edge knowledge and innovative ideas. By partnering with industry, they can translate their scientific findings into practical applications and commercial products.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest oligonucleotide synthesis market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.
The North American market for oligonucleotide synthesis is propelled by a robust pharmaceutical and biotech industry, with a strong focus on drug discovery and development. The region's emphasis on personalized medicine and targeted therapies further propels this need. Additionally, North America's sophisticated healthcare system with advanced diagnostic capabilities increases the demand for oligonucleotides in diagnostic assays. The region also hosts numerous top-tier academic and research institutes conducting extensive genomics and molecular biology research, which necessitates oligonucleotide synthesis. Moreover, strong governmental and private sector investment in healthcare and life sciences research, particularly in genomics and personalized medicine, fuels the growth of industry in North America. Moreover, the advancements in delivery systems and formulations for oligonucleotide-based therapeutics in North America demonstrate the region's commitment to pushing the boundaries of innovation in this field. These developments not only contribute to the growth of the market but also have the potential to revolutionize the treatment of various diseases, including genetic disorders, cancers, and rare diseases.
The global oligonucleotide synthesis market is experiencing significant growth due to the escalating investments in the development of new production facilities, upgrading existing ones, and implementing more efficient production processes. Therefore, Companies are heavily investing in research and development to innovate their offerings, including developing new synthesis techniques, improving the scale and accuracy of synthesis, and creating new types of oligonucleotide products to support various applications in diagnostics, therapeutics, and research. Along with this, companies are entering into strategic collaborations, partnerships, and acquisitions to co-develop oligonucleotide-based drugs, share technology and expertise, or expand into new markets. In addition, the introduction of therapeutics, such as antisense oligonucleotides, siRNAs, and miRNAs, offer new avenues for treating a wide range of diseases, including genetic disorders and cancers is positively influencing the market. Furthermore, key players are offering services for the custom synthesis of oligonucleotides. This allows researchers and developers to order specific oligonucleotide sequences tailored to their needs, which is particularly important in fields like genomics, molecular biology, and personalized medicine.
Agilent Technologies Inc.
Biolegio B.V.
Bio-Synthesis Inc
Eurofins Genomics
GenScript
Horizon Discovery Ltd
Integrated DNA Technologies Inc (Danaher Corporation)
Kaneka Eurogentec S.A. (Kaneka Corporation)
LGC Limited
Nitto Denko Avecia Inc (Nitto Denko Corporation)
Thermo Fisher Scientific Inc.
In May 2023, GenScript increased the size of its principal manufacturing plant in Zhenjiang, Jiangsu, China for the manufacture of oligonucleotides and peptides. The expansion builds on GenScript's history of providing top-notch oligo and peptides to scientists all across the world for 20 years.
In January 2023, Agilent Technologies Inc. announced to increase its production of therapeutic nucleic acids, also known as oligonucleotides. The initiative is the most recent in a series of investments done by the sector in response to rapid development. At Agilent's plant in Frederick, Colorado, where the installation of a line announced in 2020 is slated to commence operating later this year, the project will add two oligonucleotide production lines.
In February 2022, Kaneka Eurogentec S.A. (Kaneka Corporation) stated that a 25 g batch of mRNA for a US customer had been successfully manufactured at its mRNA synthesis facility. In its present facility in Belgium, Eurogentec's GMP mRNA production service provides in vitro transcription (IVT), purification, quality control, and batch release of GMP material up to 25 g scale.